Saturday, Aug 08, 2020 | Last Update : 09:02 PM IST

137th Day Of Lockdown

Maharashtra49026232728117092 Tamil Nadu2850242275754690 Andhra Pradesh2069601204641842 Karnataka164924842322998 Delhi1427231282324082 Uttar Pradesh113378668341981 West Bengal89666630601954 Bihar7179446294400 Gujarat68855517922604 Assam5549737225132 Rajasthan4941835186763 Odisha4255028698292 Haryana4005433444467 Madhya Pradesh3729827621962 Kerala3170019147103 Jammu and Kashmir2392716218449 Punjab2193014040539 Jharkhand165427503154 Chhatisgarh11408831987 Uttarakhand89015731112 Goa7947559570 Telangana751354330615 Tripura6014408437 Puducherry5123291475 Manipur3466192610 Himachal Pradesh3206200813 Nagaland26578247 Arunachal Pradesh204913263 Chandigarh137482023 Meghalaya10234236 Sikkim8544061 Mizoram5672890
  Life   Health  16 Dec 2019  Scientists unclear on how brain change can lead to Alzheimer’s

Scientists unclear on how brain change can lead to Alzheimer’s

Published : Dec 16, 2019, 11:06 am IST
Updated : Dec 16, 2019, 11:06 am IST

Study shows these Alzheimer's drug candidates reverse broader ageing.

The research was published in the journal eLife. (Photo: ANI)
 The research was published in the journal eLife. (Photo: ANI)

Washington: A new study suggests that the Alzheimer's drug candidates CMS121 and J147 may be useful for treating a broader array of conditions and points out a new pathway that links normal ageing to Alzheimer's disease.

According to Pamela Maher, a senior staff scientist at Salk and a co-corresponding author of the new paper, "This study further validated these two compounds CMS121 and J147, not only as Alzheimer's drug candidates but also as potentially more widely useful for their anti-ageing effects,"


Old age is the biggest risk factor for Alzheimer's disease -- above the age of 65, a person's risk of developing the disease doubles about every five years. However, at a molecular level, scientists aren't sure what occurs in the brain with ageing that contributes to Alzheimer's.

"The contribution of old age-associated detrimental processes to the disease has been largely neglected in Alzheimer's disease drug discovery," says Antonio Currais, a Salk staff scientist and first author of the new paper.

Maher and David Schubert, the head of Salk's Cellular Neurobiology Lab, previously developed CMS121 and J147, variants of plant compounds with medicinal properties. Both compounds tested positive for their ability to keep neurons alive when exposed to cellular forms of stress related to ageing and Alzheimer's disease. Since then, the researchers have used the drug candidates to treat Alzheimer's in animal models of the disease.


But experiments revealing exactly how the compounds work suggested that they were targeting molecular pathways also known to be important in longevity and ageing. "The bottom line was that these two compounds prevent molecular changes that are associated with ageing," says Maher.

"There was already some data from human studies that the function of mitochondria is negatively impacted in ageing and that it's worse in the context of Alzheimer's," says Maher. "This helps solidify that link."

Tags: alzheimers, depression, anxiety